Sleep | Phase II Developments | Pipeline Prospector

Adare Pharma Solutions

Transforming oral delivery challenges into proprietary product solutions.

United States

Contact Supplier

Virtual Booth

CPhI North America 2021

Exhibiting

Request a Meeting Now

Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy

Lead Product(s): Mazindol

Therapeutic Area: Sleep Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: NLS Pharmaceutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 13, 2020

Details:

NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

Apnimed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

Lead Product(s): Aroxybutynin,Atomoxetin

Therapeutic Area: Sleep Product Name: AD109

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Morningside Ventures

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 25, 2021

Details:

The proceeds will support Apnimed’s ongoing development and commercialization plans. The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea, which is currently in late-stage Phase 2 clinical trials.